JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 180 filers reported holding JUNO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.57 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $7,762,000 | +272.6% | 169,809 | +265.7% | 0.00% | +200.0% |
| Q3 2017 | $2,083,000 | +31.5% | 46,435 | -12.4% | 0.00% | – |
| Q2 2017 | $1,584,000 | +33.8% | 52,994 | -0.7% | 0.00% | – |
| Q1 2017 | $1,184,000 | +239.3% | 53,346 | +188.4% | 0.00% | – |
| Q4 2016 | $349,000 | +24.2% | 18,500 | +97.2% | 0.00% | – |
| Q3 2016 | $281,000 | +1.1% | 9,380 | +29.9% | 0.00% | – |
| Q2 2016 | $278,000 | -49.2% | 7,222 | -49.7% | 0.00% | – |
| Q1 2016 | $547,000 | +26.0% | 14,366 | +45.4% | 0.00% | – |
| Q4 2015 | $434,000 | -10.0% | 9,877 | -16.5% | 0.00% | – |
| Q3 2015 | $482,000 | -16.9% | 11,835 | +8.9% | 0.00% | – |
| Q2 2015 | $580,000 | +199.0% | 10,871 | +239.3% | 0.00% | – |
| Q1 2015 | $194,000 | -97.5% | 3,204 | -97.9% | 0.00% | -100.0% |
| Q4 2014 | $7,833,000 | – | 150,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |